Unitedhealth Group Stock Earnings Reports

UnitedHealth Group reported a solid Q1 2026 with across-the-board outperformance vs. plan and updated full-year outlook. Reported adjusted EPS was $7.23, revenues were $111.7 billion (up ~2% YoY), and total domestic members were 49.1 million. The company reported an improved medical care ratio (83.9% vs. 84.8% a year ago), benefited modestly from favorable prior‑period reserve development (~$500M net PYD) and seasonal dynamics, and generated strong operating cash flow ($8.9B). Optum Health delivered $1.3B of adjusted earnings driven by pricing, operational improvements and favorable prior‑period development; management views this as moving toward the $1.575B guide run-rate after adjusting for one-off items. Optum Rx added ~800 clients and emphasized digital/AI tools that sped approvals and reduced appeals. Optum Insight is accelerating AI-first products (Optum Real, digital prior auth), with Optum Insight/Optum Rx more back‑half weighted in earnings cadence while UnitedHealthcare and Optum Health are first‑half weighted. The company plans nearly $1.5B of AI investment in 2026, expects a conservative 2:1 return on many projects within 12–18 months, and intends to commercialize internal AI improvements through Optum Insight. Management remains focused on margin recovery and product stability (deliberate moderation of membership growth), continued advocacy and work on Medicaid funding/states, reduction of prior authorizations (targeting a 30%+ reduction in medical prior auths this year), and expanded support for rural providers (faster payments, prior auth relief). Capital priorities: reduce debt-to-capital toward 40% and accelerate buybacks — at least $2B in repurchases expected by end of Q2 — while remaining active on strategic M&A. The company updated full-year EPS outlook to greater than $18.25 per share. Key risks discussed: elevated utilization/medical trends (particularly Medicare Advantage and Medicaid funding mismatches), regulatory/policy developments affecting PBM and Medicare risk adjustment, and the need to prudently scale AI across the enterprise.